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This study assessed the presence of 41 pharmaceuticals in wastewater samples from the 
north of Spain. The samples under study were collected during a week, before the treatment 
(influent) and after treatment (effluent) in a wastewater treatment plant (WWTP). Additionally, 
samples reaching the inlet of the WWTP from hospital discharge were also collected. The 
wastewater samples were analysed by ultra-high performance liquid chromatography coupled 
to tandem mass spectrometry using triple quadrupole analyzer (UHPLC-MS/MS QqQ) due to its 
great selectivity and sensitivity. Analyses were performed by direct injection (DI) of the samples; 
so, pre-concentration treatments were avoided. Moreover, in order to correct matrix effects, 
Isotopically-Labelled Internal Standards (ILIS) available for some pharmaceuticals were added to 
the samples. Acetaminophen and Gabapentin were the most frequently detected compounds in 
both influent wastewater (IWW) and Hospital discharge. In EWW, it was observed a decrease in 
the concentrations of pharmaceuticals in comparison to the influent samples. The removal 
efficiency (RE) (%) was calculated by comparing the mass load of the influent and the effluent 
samples. From the 30 compounds detected in wastewater, only three pharmaceuticals 
(Acetaminophen, Atorvastatin and Enalapril) presented a 100% RE, which means that they were 
completely eliminated after passing through the WWTP. The results of this work indicate that 
most of pharmaceuticals under study are present in treated wastewater, and consequently they 
reach the aquatic environment. Hazard quotients (HQ) were calculated to assess the potential 
environmental risks of these pharmaceuticals. The results showed that generally there are not 
significant risks associated to the presence of pharmaceuticals in the aquatic environment 
although Ciprofloxacin, Diclofenac, Norfloxacin and Venlafaxine presented an HQ > 1 implying 
that the amount of these compounds released into the environment is above the non-effect 
concentration. The results from this study contribute to the better understanding of potential 
risks associated to the presence of pharmaceuticals in urban wastewater and their impact on 
the aquatic environment. 







Water is essential for life. It is a fundamental component of the nature and it is necessary 
for the living beings, who are composed by around 70% of water. Water acts as a transporter of 
nutrients, among other functions for the living beings, and it is also used to cultivate lands, 
breeding of cattle… The aquatic living beings spend most of their lives in rivers, oceans and lakes.   
For that many aforementioned reasons, it is why that the water should be kept free from waste 
and micropollutants. Water is considered as polluted if it contains some substances or if it exists 
a specific condition that does not allow the water to be used for other purposes (Owa, 2014). 
 
“In the European Union (EU) around 3000 different Pharmaceutically Active Compounds 
(PhACs) are used in human medicine belonging to different medicinal classes” (Gros et al., 2010). 
These pharmaceuticals, after being consumed, are excreted via urine and faeces to the aquatic 
environment (Gaso-Sokac et al., 2017) so it can imply a potential environmental threat (Boix et 
al., 2015). Therefore, the scientific interest to know the presence and the effects of PhACs and 
other compounds of emerging concern in the aquatic environment has increased in the last few 
years (Gracia-Lor et al., 2011; Martínez-Morcillo et al., 2020). 
 
In order to avoid the presence of the pharmaceuticals and other compounds, such as 
pesticides and illicit drugs in the aquatic environment, most cities have at least one wastewater 
treatment plant (WWTP). With physical, chemical and biological processes herein, the WWTP 
should be able to eliminate most of the emergent contaminants. However, the wide majority of 
conventional WWTPs do not completely eliminate these compounds, and commonly only a 
partial or even null elimination is reached. Some studies (Radjenović et al., 2009) suggest an 
improvement and implementation of technologies of advanced treatment in order to manage 
high quality treated effluents.  
 
“Among pharmaceuticals, the presence of antibiotics in water causes more concern 
because they can induce bacterial resistance, even at low concentration, through their 
continuous exposure” (Gracia-Lor et al., 2011). So, different studies (Li et al., 2019; Na et al., 
2019) have opted to evaluate the risk that the emerging contaminants generate with a 
parameter called Hazard Quotient (HQ), which in case of being higher or equal to one, the 
studied pharmaceutical is considered dangerous for aquatic environment.  
 
The main objectives of this work are 1) to investigate the presence of 41 
pharmaceuticals in the wastewater, both in the influent wastewater (IWW) and effluent 
wastewater (EWW) of a WWTP as well as an hospital discharge in a location from the north 
Spain; 2) to calculate the removal efficiency (RE) for pharmaceuticals of the WWTP; 3) to 
evaluate the potential environmental impact that these pharmaceuticals might produce. In 
order to carry out this study, the highly sensitive technique resulting from the combination of 
ultra-high performance liquid chromatography (UHPLC) with MS/MS using triple quadrupole 
(QqQ) has been used. In order to minimise issues associated with the manipulation of samples, 
direct injection (DI) has been used for analysis. Moreover, in order to correct the matrix effect, 
different isotope-labelled internal standards (ILIS) have been added to the standards used for 








1.1. Analytical techniques 
 
The analytical technique used in this study was ultra-high performance liquid 
chromatography coupled to tandem mass spectrometry (UHPLC-MS/MS) with triple quadrupole 
(QqQ). It was selected by different reasons: excellent sensitivity and selectivity, robustness at 
low concentration levels and fully compatible with aqueous samples without the need to make 
solvent exchange. Moreover, recent advances in MS instrumentation have made possible the 
direct injection of samples, reaching concentrations at the sub-ppb levels without any type of 
sample treatment, and minimizing analytical errors associated to sample manipulation. 
 
1.1.1. Ultra-high performance liquid chromatography (UHPLC) 
 
Chromatography may be defined as a physical method of separation in which the 
mixture to resolve is introduced in a system formed by a fluid (mobile phase) that moves around 
in a close contact with a solid or liquid phase, which is immobile during the process (stationary 
phase). According to the characteristics of the mobile phase, the chromatography may be 
divided into three types: liquid, gaseous and supercritical fluids. This section focuses on the 
liquid chromatography. “UHPLC separations represent separations performed with columns 
packed with sub-2µm fully porous particles or sub-3µm core-shell particles, respectively, in 
optimized low-dispersion high-pressure LC systems with the aim to achieve fast and high-
resolution analyses” (Nováková et al., 2017).  
 
The chromatographic technique has been modified and improved through the years. 
Since 15 years ago, important advances have taken place in conventional High Performance 
Liquid Chromatography (HPLC). These advances include improvements in the stationary phase 
and in the instrumentation (Nováková et al., 2017). The decrease of the particle size improves 
the chromatographic separation, as demonstrated in the Van Deemter’s theory (Equation 1) 
because the efficiency that corresponds to the height of the plate (H) is in proportion to the 
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The sample is introduced in the column together with mobile phase thanks to a pump. 
According to the polarity of the compounds that are in the sample in the stationary phase and 
mobile phase, these compounds will be retained and eluted at different times. As a result, 
different chromatograms will be observed at different retention times. A detector is needed in 
order to transform these chromatograms into more comprehensible information. Although 










1.1.2. Mass spectrometry. Triple quadrupole instruments (QqQ) 
Mass spectrometry (MS), is an analytical technique that produces ions and separates 
them. MS classifies the ions in relation to time and space in the gaseous phase according to the 
relation m/z. The result is a plot than represents relative intensity vs m/z. It is a very sensitive 
technique and it is commonly used in different fields. It is important its use in environmental 
sciences with the purpose of studying the presence of organic pollutants (Hernández et al., 
2012). 
The sample is in liquid condition in LC but as it has been previously mentioned, the MS 
works in the gaseous phase, so it is needed a phase change that is produced thanks to the 
electrospray ionization (ESI). “ESI is considered as the most important ionization technique for 
coupling between LC and MS” (Nováková et al., 2017). A voltage and high temperature are 
applied to the sample that evaporates the solvent of the droplets formed and ends up 
generating ionic species.  
The essential part of the MS is the analyser. The resolution (capacity of differentiating 
between similar masses), system’s sensitivity, the capacity of measuring the exact mass and 
kinetics depend on the analyser. Moreover, its function is to separate the ions based on their 
m/z ratio. In this study, a triple quadrupole (QqQ) analyser has been used for analysis. The QqQ 
consists of four circular parallel bars. The ions get separated because of their stability in the 
electric fields applied to bars. The QqQ is based on the control of the transition among the 
molecular ions (or precursor ions) and the ions of the fragments (or product ions). To this end, 
specific amount of m/z are allowed throughout the first quadrupole (Q1).  Afterwards, in the 
collision cell (second quadrupole q2), a collision energy is applied in order to fragment the 
precursor ion (generated in Q1) and to generate product ions. Finally, the third quadrupole (Q3) 
is designed to isolate the specific m/z. Accordingly, after the selection of the molecular ions in 
the Q1, they get fragmented in the collision cell so at the end, only some ions in Q3 are traced, 
which results in the monitoring of the transitions among the molecular ions and the fragments. 
Only one ion with the correct m/z will have the correct trajectory and will get to the detector 
(Agilent Technologies, 2016; Heeren, 2006). 
Analysis have been made with LC-MS/MS QqQ working under the Selected Reaction 
Monitoring (SRM) mode, i.e. a precursor ion in selected, typically the [M+H]+, in the first 
quadrupole, and specific product ins are measured in the third quadrupole. In other words, 
several transitions “precursor ion > product ion” are measured, one of then used for 
quantification (known as Quantification transition), which commonly is the most abundant, and 
the remaining ones, used for confirmation of the identify (known as qualitative transitions). 
 
1.2. Importance of Isotopically-labelled internal standards 
 
Although UHPLC-MS/MS is widely accepted for pharmaceuticals analysis, there is an 
issue of major concern when applied to complex-matrix sample. The presence of coeluting 
compounds with the analytes of interest might alter the ionisation process by default (ionization  
suppression) or by excess (ionization enhancement) (Gracia-Lor et al., 2011). This is the so called, 





and the quantification of the analyte (Bijlsma et al., 2014). Matrix effect can be very high in 
complex matrix samples, such as wastewater, and therefore is necessary its appropriate 
correction to ensure the reliability of data reported. 
 
The ILIS are compounds isotopically marked that are used as surrogates in order to 
compensate the matrix effect and the possible losses during sample treatment (Bijlsma et al., 
2014; Botero-Coy et al., 2018). The high cost and low commercial availability of ILIS for some 
compounds is a limitation to apply this approach, which however is the recommended when 
only a few pharmaceuticals are under study (Botero-Coy et al., 2018). More specifically, in this 
study 15 ILIS have been used and they have contributed to the satisfactory correction of matrix 
effects for around half of the compounds investigated.  
 
1.3. Removal efficiency of Wastewater treatment plant 
 
In order to maintain aquatic systems, such as rivers, sea or lakes, free from pollution, it 
is necessary the application of appropriate treatments for removal of organic contaminants in 
the WWTPs. The treatments are commonly based on chemical, physical and biological processes 
that allow the elimination of the majority of organic matter. However, many organic micro-
pollutants are not efficiently removed using the conventional treatments applied. Therefore, 
EWW usually contain an amount of pollutants such as pharmaceuticals, pesticides or drugs, 
among others. 
 
In order to calculate the removal efficiency (RE), it is convenient to calculate the daily 
mass loads because in this way the calculation is more realistic than just comparing 
concentrations in IWW and EWW. The mass load (Equation 2) is calculated (e.g. ng/day), 
considering the daily IWW flow (F), shown in Table 3, and the concentration found in the sample 
extract (C). In order to estimate the efficiency of the elimination of the plant, the mass loads of 
the studied pharmaceuticals in IWW and EWW are compared. RE is calculated by applying 
Equation 3, where LIWW is the load of the influent at day x and LEWW is the load of the effluent at 
day x + 1, assuming in this way a residence time at the plant of approximately 24h. The result is 
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) = 𝐶 · 𝐹 ·  10−3 (Equation 2) 





1.4. Environmental risk assessment 
 
The increasing use of pharmaceuticals and personal care products (PPCPs) entails a 
continuous increase of their presence in wastewater (Li et al., 2019). For this reason, scientific 
attention on the presence and effects of PhACs and other compounds of emerging concern in 
aquatic systems has experienced a notable increase over the last decades (Martínez-Morcillo et 
al., 2020).  
 
These organic micro-pollutants may generate a consequent impact on the environment, 
also affecting the growth and reproduction of microorganisms (Li et al., 2019). Therefore, 
several studies in different research fields have been carried out. Liu et al. (X. Liu et al., 2020) 
evaluated the danger of the bioaccumulation of the PPCPs in different food such as cucumber, 
eggplant, wheat and long bean. Moreover, they also analysed the risk to human health 
associated with the consumption of these crops. Some studies (Prosser & Sibley, 2015) 
examined the manure among others in order to check if the plant tissue was free of PPCPs. A 
study carried out in Galicia (Martínez-Morcillo et al., 2020) evaluated the risk for the human 
health when consuming seafood species that contain pharmaceutical compounds.  
 
The WWTPs are considered as one of the main sources of pharmaceutical wastes in the 
aquatic system. However, the problem of WWTPs is that they mainly work to eliminate the 
already known macro-pollutants (solids, nutrients and total organic matter) and they do not 
focus on the emerging pollutants such as pharmaceuticals (Sim et al., 2010). Furthermore, 
although in the north of Europe many WWTPs include tertiary wastewater treatment, in other 
Countries, Spain included, only two treatments are usually applied (Gros et al., 2010). For this 
reason, the high concentration of the pharmaceuticals in the wastewater might be attributed to 
a poor removal in the WWTP (X. Liu et al., 2020). 
 
The parent pharmaceuticals reach wastewater through urine and/or faeces (Gaso-Sokac 
et al., 2017), but a great part of the compound is eliminated as a variety of free metabolites 
(transformation products) (Gracia-Lor et al., 2014; Han & Lee, 2017) or as conjugates of 
glucuronic and sulphuric acid (Gros et al., 2010). Some data reported (Han & Lee, 2017; X. Liu et 
al., 2020) show that the potential risk caused by some metabolites may exceed their 
predecessors. 
 
Due to the potential problems derived from their presence in the aquatic environment, 
it is necessary to evaluate the environmental risk that PPCPs and their metabolites may produce. 
A possible way to evaluate the risks is through the use of the Hazard Quotients HQ. The HQ was 
determined in this work based on several studies (Li et al., 2019; Na et al., 2019) by dividing the 
measured environmental concentration (MEC) by the predicted non-effect concentration 
(PNEC). When HQ is equal or higher than one, it suggest that the substance may cause potential 













The three main objectives of this work were: 
 
- To detect and quantify 41 pharmaceuticals in different wastewater of north of 
Spain, through the use of UHPLC-MS/MS with QqQ. These wastewaters are IWW, 
EWW and Hospital discharge.  
- To estimate WWTP removal efficiency for pharmaceuticals by comparison of IWW 
and EWW samples. 
- To evaluate the possible environmental impact that drugs can generate in the 








3. Materials and methods 
 
3.1. Pharmaceutical standards and reagents 
 
Pharmaceutical reference standards were purchased from different companies: Sigma-
Aldrich (St Louis, MO, USA), LGC Promochem (London, UK), Toronto Research Chemicals 
(Ontario, Canada), Across Organics (Geel, Belgium), Bayer Hispania (Barcelona, Spain), Fort 
Dodge Veterinaria (Gerona, Spain), Vetoquinol Industrial (Madrid, Spain) and Aventis Pharma 
(Madrid, Spain). Moreover, the ILIS were from CDN Isotopes (Quebec, Canada), Toronto 
Research Chemicals, Cambridge Isotope Laboratories (Andover, MA, USA), Sigma-Aldrich (St 
Louis, MO, USA) and Cerilliant (Texas, USA). All the reference standards obtained from the 
aforementioned sources presented high purity levels of more than 93%.  
 
Stock standard solutions of each compound were prepared at 500 mg/L in methanol or 
acetonitrile and were stored at -20ºC. The individual stock solutions were diluted ten times with 
methanol in order to prepare 50 mg/L intermediate solutions. Finally, mixed working solutions 
were prepared by dissolving intermediate solutions in water. These working solutions contained 
all the analytes, so they were used to prepare the calibration standards and for spiking samples.  
 
A Milli-Q water purification system (Millipore, Bedford, MA, USA) was used to purify 
water through filtration, osmosis and other processes so as to obtain LC-MS grade water. 
Besides, LC-MS grade methanol (MeOH), LC-MS grade acetonitrile (ACN), formic acid (HCOOH, 
content > 98%) and ammonium acetate (NH4AC, reagent grade), were acquired from Scharlab 
(Barcelona, Spain).  
 
3.2. Description of the wastewater treatment plant 
 
The wastewater treatment plant (WWTP) included in this study treats urban wastewater 
from the public sanitation system of different towns. The WWTP is located in the north of Spain 
and it also receives different authorized industrial discharges, mainly related to the chemical, 
pharmaceutical, food and services sectors.  
 
The WWTP applies a pre-treatment with a maximum flow rate of 41,208 m3/day and 
A20 type biological process with a maximum of 20,640 m3/day. This biological process removes 
organic matter, nitrogen and phosphorus with anaerobic, anoxic chambers and aerated carousel 
channels. Moreover, it is a variant of the conventional treatment of active sludge, which 
incorporates an anaerobic zone at the reactor inlet. In this reactor, which has a capacity of 
16,076 m3, the influent wastewater and recirculated sludge are received, producing the 
fermentation reaction and phosphate elimination. The biologically treated effluent ends in two 
circular decanters of 28 meters in diameter, so the treated water from WWTP is returned to the 
river. 
The quality parameters of the WWTP’s effluent must be in accordance with the 
requirements of the Water Framework Directive 2000/60/EC (Directive 2000/60/EC of the 
European Parliament and of the Council of 23 October 2000 establishing a Framework for 
Community Action in the Field of Water Policy., 2000) (e.g. organic matter, suspended solids and 
nutrients: nitrogen and phosphorus) as shown in Table 1. 






















3.3. Selected pharmaceuticals  
 
In preliminary stages of the study, a high resolution mass spectrometry screening was 
carried out and the list of pharmaceuticals to be included in this particular study was based on 
the results obtained in the screening. A total of 41 pharmaceuticals were selected including 17 
compounds previously identified and confirmed in the screening (data not published) and 24 
additional compounds of interest based on the prevalence of use and availability of reference 





3.4.1. Sample collection 
 
IWW and EWW 24-h composite samples at the inlet and outlet of the WWTP, 
respectively, were collected during seven consecutive days in September. Additionally, daily 
composite samples reaching the inlet of the WWTP from hospital discharge were also collected. 
All the samples were collected in high-density polyethylene bottles, stored at < -20ºC, and 
transported to the laboratory once the last sample of the week was collected. After reception 
in the laboratory, samples were stored in the dark at -20ºC and analysed within 2 weeks. Water 









Parameter Emission limit 
pH Between 6-9 
Suspended solids < 15 mg/L 
BOD5 < 12 mg O2/L 
COD < 60 mg O2/L 
Total ammonium < 3 mg NH4/L 
Nitrates < 35 mg NO3/L 
Kjeldahl nitrogen < 5 mg N/L 
Total nitrogen < 15 mg N/L 
Total phosphorus < 2 mg P/L 









Atorvastatin Hypolipidemic agent 
Azithromycin Antibiotic 










Gemfibrozil Hypolipidemic agent 
Irbesartan Antihypertensive 
Ketoprofen Nonsteroidal anti-inflammatory 




Metoprolol Beta-blocker agent 
Metronidazole Antibiotic 
Nalidixic acid Antibiotic 
Naproxen Nonsteroidal anti-inflammatory 
Norfloxacin Antibiotic 
Omeprazole sulfide, 4-OH Antiulcer drug 
Oxolinic acid Antibiotic 
Pantoprazole Antiulcer drug 
Phenazone Nonsteroidal anti-inflammatory 
Primidone Antiepileptic 
Roxithromycin Antibiotic 



















3.4.2. Analytical procedure 
 
Sample analysis was performed according to previously developed, validated and 
published methodologies (Boix et al., 2015; Botero-Coy et al., 2018). Briefly, depending on the 
origin of the samples (i.e. IWW, hospital discharge, EWW), two different sample treatments 
were applied. Firstly, 1ml of raw WW sample was centrifuged at 12.000 rpm for 10 min. For IWW 
and Hospital discharge samples, a x5 dilution was performed with Milli-Q water in order to 
reduce the matrix complexity. For this purpose, a 200 L-aliquot of the centrifuged sample was 
diluted with 750 L of Milli-Q water and 50 L of mix ILIS solution (2 µg/L). The EWW samples 
were diluted x2, so a 500 L- aliquot of the centrifuged EWW sample was diluted with 450 µL 
Milli-Q water and 50 L of mix ILIS solution (2 µg/L). ILIS were at a final concentration of 0.1 µg/L 
in all samples. Finally, 50 L of diluted samples were injected in the UHPLC-MS/MS system in 
order to perform the analyses. Figure 1 shows the schematic analytical procedure followed for 




Figure 1. Flow chart for the analysis of (a) IWW and Hospital and (b) EWW samples. 
200 L IWW or Hospital 
Discharge
Add 750 L Milli-Q H20
Add 50 L mix ILIS 
solution (0.2 g/L)
Extract 50 L (0.1 g/L)
UHPLC-MS/MS
500 L EWW
Add 450 L Milli-Q H20
Add 50 L mix ILIS 
solution (0.2 g/L)
Extract 50 L (0.1 g/L)
UHPLC-MS/MS
1 mL raw WW sample
Centrifuging 10 min 
12,000 rpm
a) b) 











UHPLC analysis was carried out with a Waters ACQUITY ultra performance liquid 
chromatography (UPLCTM) system (Waters Corp., Milford, MA, USA). A CORTECS C18 column (100 
x 2.1 mm i.d., particle size 2.7 m) (Waters) with a constant flow rate of 0.4 mL/min was used 
for chromatographic separation. The mobile phases were A= methanol LC-MS and B= water LC-
MS, both with 0.01% HCOOH and 1 mM ammonium acetate. Finally, the column was kept at 
40C and the percentage of solvent A was changed as follows: 0 min, 5% A; 7 min, 95% A; 8 min, 
95% A; 8.1 min, 5% A for the re-equilibration of the column with a total run time of 9.5 min.  
The UPLC system was interfaced to a triple quadrupole mass spectrometer Xevo TQ-STM 
(Waters Micromass, Manchester, UK), equipped with an orthogonal Z-spray electrospray 
ionization interface (ESI) and operated in positive and negative ion mode. Furthermore, a 
capillary voltage was fixed at 3.5 kV (ESI+) and 2 kV (ESI-) with a cone voltage of 10 V. Then, 
nitrogen (Praixar, Valencia, Spain) was optimized at 250 L/h to be used as a cone gas and 
optimized at 1200 L/h to be used as a desolvation gas. Regarding the operation in MS/MS mode, 
the collision gas was Argon 99.995% (Praixar, Valencia, Spain) with a flow of 0.15 mL/min in the 
collision cell. Moreover, the desolvation temperature was set to 650C and the source 
temperature was set to 150C. 
 All the data were acquired using MassLynx Software v 4.1 (Waters Corporation) and the 










Hospital IWW EWW 
Monday na 22.120 16.980 
Tuesday na 20.828 16.830 
Wednesday  na 17.184 18.110 
Thursday na 17.992 16.680 
Friday na 22.208 16.590 
Saturday na 20.796 15.860 
Sunday na 18.996 18.680 
na: data not available. 






3.5. MS conditions for target compounds 
 
Out of 41 compounds, 36 were determined with ESI operating in positive ionization 
mode and using the protonate molecule [M+H]+ as precursor ion. The remaining 5 compounds 
were determined in negative ionization using [M-H]- as precursor ion, as shown in Table 4.  
 
The acquisition of three SRM transitions for every compound allowed the simultaneous 
quantification and identification of the positive findings. In addition, 15 isotopically labelled 
internal standards were used for matrix effects correction. Regarding the reliable identification 
of the compounds found in the sample, the calculation of the ion ratios (peak area) between the 
confirmation (q1 and q2) and quantification (Q) transitions (q1/Q and q2/Q enabled the 
confirmation of the identity. The finding was considered as positive when at least one ion-ratio 
and the retention time of the compound in sample were within the tolerance ranges of the 
deviation compared standards used for calibration (maximum deviation  30% for ion ratio,  
0.1 min for the retention time) (Guidance document on analytical quality control and method 
validation procedures for pesticides residues analysis in food and feed (SANTE/12682/2019)., 
2019).  
 
The selected transitions (quantification -Q- and confirmation -q-), Collision Energies (CE), 
Limits of Quantification (LOQ), ILIS used for matrix effect correction, and the retention times are 
shown in Table 4 for each compound. Cone voltage was 10 V for all compounds.  
 
 
3.6. Method performance 
 
The quantification transition (Q) and external calibration with standards in solvent were 
used in order to quantify the analytes. In those cases that the analyte-ILIS was available, relative 
areas were used for quantification. At least eight-point calibration curves (0-20.000 ng/L) were 
included at the beginning and the end of each sequence of analysis. Linearity was assumed when 
regression coefficient (R) was > 0.99 with residuals lower than 30%. Regarding the LOQ, it was 
considered as the lowest calibration level (LCL) taking into account the sample dilution, i.e. LOQs 
were LCLx5 for IWW and hospital discharge and LCLx2 for EWW.  
 
Quality control (QC) samples consisted of real-word wastewaters, which were fortified 
at two concentration levels: 0.5 and 5 g/L (for Hospital and IWW) and 0.2 and 2 g/L (for EWW). 
QCs and the samples were treated in the same way and therefore injected in every batch of 
analysed samples. QCs recoveries were considered as satisfactory when they were between 60% 
and 140% (Guidance document on analytical quality control and method validation procedures 













Table 4. Conditions of analysis by UHPLC-MS/MS. 














152 > 110 15 152 > 93 




Alprazolam + (-) 309 > 281 25 309 > 205 




Atorvastatin + Atorvastatin-d5 559 > 440 20 559 > 466  




Azithromycin + Azitromycin-d3 749.4 > 591.4 25 749.4 > 82.9 




Bezafibrate - (-) 360 > 274 20 360 > 154 




Carbamazepine + Carbamazepine 
10, 11-epoxide-
d10 
237 > 194 20 
237 > 179 




Ciprofloxacin + Ciprofloxacin-d8 332 > 231 25 332 > 288 




Clarithromycin + (-) 590 > 158 20 590 > 116 




Clindamycin + (-) 425.1 > 126 20 425.1 > 377 




Diclofenac + Diclofenac-d4 296.2 > 214.2 30 296.2 > 250 




Enalapril + (-) 377 > 234 15 377 > 117 






734 > 158 25 734 > 576 




Furaltadone + (-) 325 > 100 20 325 > 252 




Gabapentin + (-) 172 > 137 15 172 > 154.2 




Gemfibrozil - (-) 249 > 113 10 249 > 121 




Irbesartan + Irbesartan-d6 429 > 207 25 429 > 195 




Ketoprofen - (-) 253 > 79 10 253 > 92 




Levamisol + Cocaethylene-d8 205 > 178 20 205 > 91 




Lincomycin + (-) 407 > 126 20 407 > 359 




Lorazepam + (-) 321 > 275 20 321 > 303 




Losartan + (-) 423.1 > 207.1 15 423.1 > 377.1 




*LOQ was considered as LQLX5 for the Hospital and IWW samples, and LQLx2 for EWW samples. **LOQs for Alprazolam and 
Atorvastatin were 25 for Hospital and IWW, 5 for EWW. LOQs for Gemfibrozil were 25000 for Hospital and IWW, and 2000 for 
EWW.  ***Data not available. 
 
 






Table 4 (cont). 













Metoprolol + (-) 268.2 > 116 15 268.2 > 74 




Metronidazole + (-) 172 > 127.9 15 172 > 82.1 




Nalidixic acid + (-) 233 > 215 10 233 > 187 




Naproxen - (-) 229 > 170 20 229 > 185 




Norfloxacin + Norfloxacin-d5 320 > 233 25 320 > 276 






+ Omeprazole-d3 316 > 168 20 316 > 149 




Oxolinic acid + (-) 262 > 216 25 262 > 244 




Pantoprazole + (-) 384 > 200 10 384 > 138 




Phenazone + (-) 189.3 > 
131.1 
20 189.3 > 104.1 




Primidone + (-) 219.2 > 162 10 219.2 > 91 




Roxithromycin + (-) 679 > 158 25 679 > 116 






+ (-) 240 > 148 15 240 > 222.1 




Simvastatin + Simvastatin-d6 419.1 > 199 10 419.1 > 285 






251 > 156 15 251 > 92 






254 > 92 25 254 > 156 




Tetracycline + (-) 445 > 154 25 445 > 410 




Tramadol + (-) 264 > 58 10 264 > 121 




Trimethoprim + (-) 291 > 123 25 291 > 230 




Valsartan + Valsartan-d8 436 > 207 25 436 > 235 




Venlafaxine + Venlafaxin-d6 278 > 58 15 278 > 260 




*LOQ was considered as LQLX5 for the Hospital and IWW samples, and LQLx2 for EWW samples. **LOQs for Alprazolam and 
Atorvastatin were 25 for Hospital and IWW, 5 for EWW. LOQs for Gemfibrozil were 25000 for Hospital and IWW, and 2000 








Table 4 (cont). 
ILIS ESI Transition (Q) CE (eV) 
Acetaminophen-d4 + 156 > 114 10 
Atorvastatin-d5 + 564 > 445 20 
Azitromycin-d3 + 752.2 > 594.2 25 
Carbamazepine 10, 11- epoxide-d10 + 263 > 190 25 
Ciprofloxacin-d8 + 340.1 > 322.1 20 
Diclofenac-d4 + 300.1 > 219.2 20 
Erythromycin-13C3 + 738.1 > 161.9 35 
Irbesartan-d6 + 435.1 > 231.3 25 
Cocaethylene-d8 + 326 > 204 20 
Norfloxacin-d5 + 325 > 238 20 
Omeprazole-d3 + 349 > 198 10 
Simvastatin-d6 + 425.2 > 199.1 10 
Sulfamethoxazole-13C6 + 260 > 162 15 
Valsartan-d8 + 444 > 207 25 
Venlafaxin-d6 + 284.3 > 64.1 25 
*LOQ was considered as LQLX5 for the Hospital and IWW samples, and LQLx2 for EWW 
samples. **LOQs for Alprazolam and Atorvastatin were 25 for Hospital and IWW, 5 for 
EWW. LOQs for Gemfibrozil were 25000 for Hospital and IWW, and 2000 for EWW.  ***Data 
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4. Results and discussion 
 
4.1. Quality Control 
 
The quality control of the methodology used for the determination of drugs by UHPLC-
MS/MS was carried out through the analysis of Quality Control samples (QCs) in order to support 
the robustness, effectiveness and reliability of the method applied and support the quantitative 
data reported. Each batch analysed included at least two QCs for every type of samples (i.e. 
IWW, EWW, hospital discharge). The average recoveries (%) for the QCs prepared for IWW, 
EWW and hospital discharges (n=2) are shown in Table 5. 
 
In general, the recoveries were satisfactory with values between 60 and 140%, 
acceptable range for individual QCs values in the field of residues analysis (Guidance document 
on analytical quality control and method validation procedures for pesticides residues analysis 
in food and feed (SANTE/12682/2019)., 2019), which gives reliability to the results obtained. The 
achievement of satisfactory results for most QCs was undoubtedly facilitated by the use of a 
high number of ILIS and the absence of complex sample treatment in the analytical process. 
However, both the complexity of the sample matrix and the low analyte concentrations, make 
this type of analysis problematic. Therefore, it was necessary to find a right compromise for 
application of the analytical multiclass method to a high number of compounds.  
 
The most relevant exceptions to satisfactory QCs recoveries among the 41 investigated 
pharmaceuticals were Ciprofloxacin, Norfloxacin and Simvastatin for which average recovery 
values greater than 200% and poor reproducibility was observed, surely due to inefficient 
correction of ILIS. Other 4 compounds (i.e. Bezafibrate, Gemfibrozil, Ketoprofen and Naproxen) 
analysed in negative ESI could not be properly evaluated due to the lack of instrumental 
sensitivity at the fortified level tested. Therefore, no recovery values were included for these 
pharmaceuticals. In addition, the antibiotics Clarithromycin and Roxithromycin presented 
unsatisfactory recoveries (over 200%), especially at the high fortification levels because the 
analyte ILIS was not available for matrix effects correction. Finally, the average recovery of the 
antibiotic Azithromycin in the IWW and EWW samples was also near the acceptable range but 
slightly below 50%. 
 
Regarding the sample analysis, the failure to obtain fully satisfactory QC recoveries only 
affected to a few cases, in which positive detections were found. The most noticeable were the 
antibiotics Ciprofloxacin and Norfloxacin. Despite these two substances were found in all 
samples at concentrations above the limit of quantification, they could not be accurately 
quantified. Accordingly, for these two compounds, the presented data should be considered as 



























 Hospital IWW EWW 
Drugs 0.5 µg/L 5 µg/L 0.5 µg/L 5 µg/L 0.2 µg/L 2 µg/L 
Acetaminophen a a 132 125 97 107 
Alprazolam 82 87 110 106 101 125 
Atorvastatin 103 104 107 103 106 106 
Azithromycin 81 59 * * 15 69 
Bezafibrate - 49 - 63 - 81 
Carbamazepine 89 b 91 b 74 b 
Ciprofloxacin * * * * * * 
Clarithromycin 118 * 139 * 124 * 
Clindamycin 135 130 77 81 108 121 
Diclofenac 116 108 98 96 96 94 
Enalapril 111 104 102 107 104 106 
Erythromycin 95 108 78 103 90 108 
Furaltadone 84 100 82 74 115 95 
Gabapentin 101 122 105 109 149 117 
Gemfibrozil - - - - - - 
Irbesartan 100 108 92 100 a 106 
Ketoprofen - 66 - - - - 
Levamisole 106 125 99 121 138 176 
Lincomycin 116 89 97 110 124 108 
Lorazepam 112 98 111 93 77 100 
Losartan 115 93 106 103 105 104 
Metoprolol 103 110 110 121 112 126 
Metronidazole 72 86 98 99 103 116 
Nalidixic acid 81 95 90 94 97 96 
Naproxen - - - - - 78 
Norfloxacin * * * * * * 
Omeprazole 
sulfide, 4-OH 
73 57 96 80 67 64 
Oxolinic acid 99 83 94 79 107 85 
Recoveries outside the accepted range 60%-140% are shown in bold. a. Presence of analyte in the 
blank at high concentration, which prevents recovery calculation. b. Value not calculated due to lack 
of linearity at high concentration levels. -. Value not available due to lack of sensitivity, which 
prevents reaching the lowest tested concentration levels. *. Anomalous recovery value, not 
acceptable value. 





Table 5 (cont.) 
 
 
4.2. Occurrence of pharmaceuticals in wastewater samples 
 
In this work three types of wastewater (i.e. IWW, EWW and Hospital discharge) were 
analysed by UHPLC-MS/MS. In order to study the efficiency of the elimination of the WWTP, 
data obtained from IWW and EWW were compared. Moreover, with the results of EWW it was 
possible to know which pharmaceuticals and at which concentration end up in the environment, 
so as to evaluate the environmental impact based on the use of the HQ. In addition, Hospital 
water samples were analysed and compared with the IWW samples.  
 
It is important to highlight that most QCs of the Ciprofloxacin and Norfloxacin did not 
obtain any successful recovery so they could not be quantified with the required accuracy. 
However, these antibiotics were found in most of the water samples, presenting higher 
concentrations by far above the limit of quantification. For these two pharmaceuticals, 





















Pantoprazole 129 124 119 121 118 69 
Phenazone 138 148 114 134 81 96 
Primidone 87 88 102 105 94 106 
Roxithromycin * * * * * * 
Salbutamol 
(Albuterol) 
100 96 111 104 143 139 
Simvastatin * * * * * * 
Sulfadiazine 88 96 110 120 73 87 
Sulfamethoxazole 117 110 114 116 109 111 
Tetracycline 86 57 95 79 83 37 
Tramadol 84 93 104 103 108 115 
Trimethoprim 84 98 116 124 118 132 
Valsartan 87 126 68 70 86 103 
Venlafaxine 96 105 96 114 107 118 
Recoveries outside the accepted range 60%-140% are shown in bold. a. Presence of analyte in the 
blank at high concentration, which prevents recovery calculation. b. Value not calculated due to lack 
of linearity at high concentration levels. -. Value not available due to lack of sensitivity, which 
prevents reaching the lowest tested concentration levels. *. Anomalous recovery value, not 
acceptable value. 





4.2.1. IWW samples 
 
A total of 30 out of 41 pharmaceuticals were observed in the IWW (Table 6). In general, 
pharmaceutical concentrations for a given compound were similar throughout the week, with 
the exception for Phenazone, which could only be quantified on Monday and Sunday at quite 
different concentrations.  
 
Acetaminophen (6490 ng/L) and Gabapentin (4014 ng/L) presented the highest levels of 
concentration. Moreover, total daily mass load of each pharmaceutical (Table 7) was calculated 
in ng/day, from the Equation 2. Figure 2 and Figure 3 show the chromatograms obtained for 
positive samples containing Acetaminophen (Monday) and Gabapentin (Thursday), respectively. 
 
4.2.2. EWW samples 
 
The results of the analysis are shown in Table 8 with the concentrations expressed in 
ng/L. The total daily mass loads (mg/day) are shown in Table 9, considering the EWW flow rates 
indicated in Table 3. A total of 29 out of 41 pharmaceuticals were detected in the EWW. The 
concentrations throughout the week were constant and lower than 100 ng/L. However, 
Gabapentin, Tramadol, Irbesartan and Diclofenac presented an average concentration higher 
than 100 ng/L.  
 
 After the application of the treatment in the WWTP, the concentrations of most 
pharmaceuticals decreased, presenting levels in the EWW lower than in IWW, which reveal that 
these compounds were removed or retained in the WWTP, at least partially. However, 
Alprazolam, Clindamycin, Lorazepam, Metoprolol, Metronidazole, Nalidixic Acid, Pantoprazole 
and Salbutamol presented the same or even higher concentrations than in IWW, which 
illustrates that the treatment applied in the WWTP does not remove these pharmaceuticals. A 
similar  behaviour has been observed in other studies performed around the world (Botero-Coy 
et al., 2018; Gros et al., 2010). 
 
4.2.3. Hospital discharge samples 
 
In the Hospital discharge samples, 28 out of 41 studied pharmaceuticals were detected. 
Their concentration throughout the week of sampling were also rather constant, with the 
exception of Erythromycin, Losartan, Pantoprazole, Phenazone, Sulfamethoxazole, 
Trimetroprim, Valsartan and Ciprofloxacin. 
 
Acetaminophen and Gabapentin presented the highest levels of concentration 
throughout the week. More specifically, on Saturday, Acetaminophen presented its peak with a 
concentration of 158840 ng/L and on Friday, Gabapentin presented its peak with a 
concentration of 22947 ng/L (shown in Table 10). For the Hospital samples, it has not been 
possible to calculate the total daily mass load of the pharmaceuticals because the flow rate data 
was unknown for the analyst. 
 
For more information, see the Annex, where for each sample two types of graphs have 
been made to observe the trends for quantitative data. (Figures 6-11). 
 













Figure 3. LC-MS/MS chromatogram for Gabapentin. IWW sample collected on Thursday. 
 
 






Table 6. Concentrations (ng/L) of pharmaceuticals in IWW samples.  
Drugs Monday Tuesday Wednesday Thursday Friday Saturday Sunday 
Acetaminophen 5185 8713 7336 6649 7171 7733 2643 
Alprazolam - - - - - - d 
Atorvastatin 86 90 72 81 84 113 80 
Azithromycin d d d d d d d 
Bezafibrate - - - - - - - 
Carbamazepine d d d d d d d 
Ciprofloxacin 99439 460160 88450 48479 - - 51776 
Clarithromycin 117 96 127 76 70 101 95 
Clindamycin - - - - - d - 
Diclofenac 407 247 199 197 165 252 157 
Enalapril 45 66 51 49 49 58 34 
Erythromycin - 35 30 32 d 33 d 
Furaltadone - - - - - - - 
Gabapentin 3561 3875 4311 3641 4087 4678 3942 
Gemfibrozil - - - - - - - 
Irbesartan 215 240 189 248 224 264 185 
Ketoprofen - - - - - - - 
Levamisol 26 - 43 29 27 32 27 
Lincomycin - - - - - - - 
Lorazepam 34 29 41 35 - - - 
Losartan 156 181 156 178 165 221 120 
Metoprolol d d d - d d d 
Metronidazole d d d - - d - 
Nalidixic acid d - - - - - - 
Naproxen - d d d - d - 
Norfloxacin - 1269 1966 1030 551 178 - 
Omeprazole 
sulfide, 4-OH 
64 65 65 52 66 90 63 
Oxolinic acid - - - - - - - 
Pantoprazole - - - - - - - 
Phenazone 93 - d d - d 56 
Primidone 80 71 69 84 63 82 88 
Roxithromycin - - - - - - - 
Salbutamol 
(Albuterol) 
- d d d d d d 
Simvastatin - - - - - - - 
Sulfadiazine - - - - - - - 
Sulfamethoxazole 70 129 70 56 57 101 36 
Tetracycline 49 53 - - - - - 
Tramadol 574 570 649 593 660 730 603 
Trimethoprim 180 199 126 109 93 146 109 
Valsartan 457 552 390 602 444 651 456 
Venlafaxine 146 151 154 153 180 191 161 
-. Not detected. 
d. Detected but not quantified. Concentration below LOQ. 
Underlined. Indicative data of concentration. 
 





Table 7. Daily loads (ng/day) of pharmaceuticals in IWW samples. 
Drugs Monday Tuesday Wednesday Thursday Friday Saturday Sunday 
Acetaminophen 115 181 126 120 159 161 50 
Alprazolam - - - - - - d 
Atorvastatin 1.9 1.9 1.24 1.5 1.9 2 1.5 
Azithromycin d d d d d d d 
Bezafibrate - - - - - - - 
Carbamazepine d d d d d d d 
Ciprofloxacin 2200 9584 1520 872 - - 984 
Clarithromycin 3 2 2 1.4 1.6 2 1.8 
Clindamycin - - - - - d - 
Diclofenac 9 5 3 4 4 5 3 
Enalapril 1 1.4 - - 1.09 1..21 0.65 
Erythromycin - 0.73 0.52 0.58 d 0.69 d 
Furaltadone - - - - - - - 
Gabapentin 79 81 74 66 91 97 75 
Gemfibrozil - - - - - - - 
Irbesartan 5 5 3 5 5 6 4 
Ketoprofen - - - - - - - 
Levamisol 0.58 - 0.74 0.52 0.60 0.67 0.51 
Lincomycin - - - - - - - 
Lorazepam 0.75 0.60 0.70 0.63 - - - 
Losartan 4 4 3 3 4 5 2 
Metoprolol d d d - d d d 
Metronidazole d d d - - d - 
Nalidixic acid d - - - - - - 
Naproxen - d d d - d - 
Norfloxacin - 26 34 19 12 4 - 
Omeprazole 
sulfide, 4-OH 
1.4 1.4 1.12 0.93 1.5 1.9 1.20 
Oxolinic acid - - - - - - - 
Pantoprazole - - - - - - - 
Phenazone 2 - d d - d 1.06 
Primidone 1.8 1.5 1.19 1.5 1.4 1.7 1.7 
Roxithromycin - - - - - - - 
Salbutamol 
(Albuterol) 
- d d d d d d 
Simvastatin - - - - - - - 
Sulfadiazine - - - - - - - 
Sulfamethoxazole 1.6 3 1.20 1 1.3 2 0.68 
Tetracycline 1.08 1.10 - - - - - 
Tramadol 13 12 11 11 15 15 12 
Trimethoprim 4 4 2 2 2 3 2 
Valsartan 10 12 7 11 10 14 9 
Venlafaxine 3 3 3 3 4 4 3 
-. Not detected. 
d. Detected but not quantified. Concentration below LOQ. 
Underlined. Indicative data of concentration. 
 
 






Table 8. Concentrations (ng/L) of pharmaceuticals in EWW samples. 
Drugs Monday Tuesday Wednesday Thursday Friday Saturday Sunday 
Acetaminophen - - - - - - - 
Alprazolam d d d d d 6 d 
Atorvastatin - d - - d - - 
Azithromycin - - - - - - - 
Bezafibrate - - - - - - - 
Carbamazepine - - - - d d - 
Ciprofloxacin 1163 - 610 1558 11082 3769 - 
Clarithromycin 53 44 57 34 58 47 43 
Clindamycin d d - d d d 10 
Diclofenac 182 151 141 148 126 135 119 
Enalapril - - - - - - - 
Erythromycin 36 24 26 41 23 23 22 
Furaltadone - - - - - - - 
Gabapentin 1669 1638 1599 1550 1391 1535 1506 
Gemfibrozil - - - - - - - 
Irbesartan 150 134 167 194 191 192 195 
Ketoprofen - - - - - - - 
Levamisol 37 30 27 28 25 24 27 
Lincomycin - - - - - - - 
Lorazepam 44 44 41 31 57 41 47 
Losartan 12 13 10 d 11 15 d 
Metoprolol d d d - 10 14 d 
Metronidazole d d - d - d - 
Nalidixic acid d d d d - - d 
Naproxen - - - - - - - 
Norfloxacin - - - 2078 531 515 - 
Omeprazole 
sulfide, 4-OH 
39 40 39 37 34 36 40 
Oxolinic acid - 18 - - - - - 
Pantoprazole 21 20 19 19 17 18 23 
Phenazone d d - d d d d 
Primidone 66 59 69 74 77 74 84 
Roxithromycin - - - - - - - 
Salbutamol 
(Albuterol) 
- d d d d d d 
Simvastatin - - - - - - - 
Sulfadiazine - - - - - - - 
Sulfamethoxazole 44 46 36 31 19 18 38 
Tetracycline - 30 18 - - - d 
Tramadol - 529 503 530 - 910 271 
Trimethoprim 12 15 10 - 24 - d 
Valsartan - 31 - - 35 19 18 
Venlafaxine 184 180 162 175 155 160 191 
-. Not detected. 
d. Detected but not quantified. Concentration below LOQ. 
Underlined. Indicative data of concentration. 
 





Table 9. Daily loads (ng/day) of pharmaceuticals in EWW samples. 
Drugs Monday Tuesday Wednesday Thursday Friday Saturday Sunday 
Acetaminophen - - - - - - - 
Alprazolam d d d d d 0.10 d 
Atorvastatin - d - - d - - 
Azithromycin - - - - - - - 
Bezafibrate - - - - - - - 
Carbamazepine - - - - d d - 
Ciprofloxacin 20 - 11 26 184 60 - 
Clarithromycin 0.90 0.74 1.03 0.57 0.96 0.75 0.80 
Clindamycin d d - d d d 0.19 
Diclofenac 3 3 3 3 2 2 2 
Enalapril - - - - - - - 
Erythromycin 0.61 0.40 0.47 0.68 0.38 0.36 0.41 
Furaltadone - - - - - - - 
Gabapentin 28 28 29 26 23 24 28 
Gemfibrozil - - - - - - - 
Irbesartan 3 2 3 3 3 3 4 
Ketoprofen - - - - - - - 
Levamisol 0.63 0.50 0.49 0.47 0.41 0.38 0.50 
Lincomycin - - - - - - - 
Lorazepam 0.75 0.74 0.74 0.52 0.95 0.65 0.88 
Losartan 0.20 0.22 0.18 d 0.18 0.24 d 
Metoprolol d d d - 0.17 0.22 d 
Metronidazole d d - d - d - 
Nalidixic acid d d d d - - d 
Naproxen - - - - - - - 
Norfloxacin - - - 35 9 8 - 
Omeprazole 
sulfide, 4-OH 
0.66 0.67 0.71 0.62 0.56 0.57 0.74 
Oxolinic acid - 0.30 - - - - - 
Pantoprazole 0.36 0.34 0.34 0.32 0.28 0.29 0.43 
Phenazone d d - d d d d 
Primidone 1.12 0.99 1.3 1.23 1.3 1.17 1.6 
Roxithromycin - - - - - - - 
Salbutamol 
(Albuterol) 
- d d d d d d 
Simvastatin - - - - - - - 
Sulfadiazine - - - - - - - 
Sulfamethoxazole 0.75 0.77 0.65 0.52 0.32 0.29 0.71 
Tetracycline - 0.50 0.33 - - - d 
Tramadol - 9 9 9 - 14 5 
Trimethoprim 0.20 0.25 0.18 - 0.40 - d 
Valsartan - 0.52 - - 0.58 0.30 0.33 
Venlafaxine 3 3 3 3 3 3 4 
-. Not detected. 
d. Detected but not quantified. Concentration below LOQ. 
Underlined. Indicative data of concentration. 
 
 






Table 10. Concentrations (ng/L) of pharmaceuticals in Hospital discharge samples. 
Drugs Monday Tuesday Wednesday Thursday Friday Saturday Sunday 
Acetaminophen 144160 145630 117290 144600 115150 158840 112340 
Alprazolam d d d d - - - 
Atorvastatin 294 277 745 206 221 266 294 
Azithromycin 1140 1387 998 1134 1349 1059 130 
Bezafibrate - - - - - - - 
Carbamazepine - - - - - - - 
Ciprofloxacin 1180 4197 138890 197580 23212 112847 680508 
Clarithromycin 73 - - - 35 - - 
Clindamycin 86 167 88 83 - - - 
Diclofenac 385 237 189 221 236 331 392 
Enalapril 253 212 59 233 189 171 263 
Erythromycin 3132 296 303 525 61 436 190 
Furaltadone - - - - - - - 
Gabapentin 13995 18114 2311 13377 22947 18943 13439 
Gemfibrozil - - - - - - - 
Irbesartan 240 292 163 114 117 185 184 
Ketoprofen - - - - - - - 
Levamisol - - - - - - - 
Lincomycin - - - - - - - 
Lorazepam 235 199 96 189 - 264 169 
Losartan 105 451 96 181 146 778 450 
Metoprolol d d 25 34 - d d 
Metronidazole - - - - - - - 
Nalidixic acid - - - - - - - 
Naproxen d - d - - - - 
Norfloxacin 2154 9605 9200 14776 7264 10657 4703 
Omeprazole 
sulfide, 4-OH 
159 118 80 105 117 127 127 
Oxolinic acid - - -  - - - 
Pantoprazole 101 48 25 85 204 71 174 
Phenazone 40 - 367 - 72 - 47 
Primidone - - - - 68 - - 
Roxithromycin - - - - - - - 
Salbutamol 
(Albuterol) 
58 43 d 33 35 42 42 
Simvastatin - - - - - - - 
Sulfadiazine d d d d d d d 
Sulfamethoxazole - - - d - 144 1016 
Tetracycline - - - - - - 43 
Tramadol 1528 1388 1787 1490 1564 1740 1061 
Trimethoprim 31 d d 29 40 348 1299 
Valsartan 3404 3152 1949 5925 2737 63 2924 
Venlafaxine 1119 865 764 917 1161 1477 946 
-. Not detected. 
d. Detected but not quantified. Concentration below LOQ. 
Underlined. Indicative data of concentration. 
 




4.3. Estimation of the pharmaceuticals removal efficiency at the 
wastewater treatment plant 
 
In order to estimate the removal efficiency of the plant, Equation 3 was used, taking 
into account the values included in Table 7 and Table 9.  
 
According to the removal efficiency (RE) (%) data shown in Table 11, Acetaminophen, 
Atorvastatin and Enalapril, were totally eliminated, with an average efficiency of 100%. 
Furthermore, Losartan, Trimetroprim and Valsartan, also presented a great efficiency of 
elimination but lower than 100%. For other compounds RE was around or higher than 50%, such 
as Clarithromycin, Diclofenac, Gabapentin, Omeprazole sulfide 4-OH, Sulfamethoxazole and 
Tetracycline. Moreover, Irbesartan, Levamisol, Primidone and Venlafaxine present an average 
efficiency of less 35%, which means that the treatments applied in this WWTP in order to 
eliminate the compounds does not efficiently eliminate these pharmaceuticals. Figure 4 shows 
in a more visual way the average RE for one-week data expressed in %.  
 
Table 11 also includes pharmaceuticals (e.g. Alprazolam, Azithromycin, Clindamycin, 
Metoprolol) with concentrations lower than the limit of the quantification (marked with 
different characters). For these compounds, a removal efficiency could not be calculated, 
because it was not possible to obtain a numerical value, being the present compound as d. 
 
Erythromycin, Lorazepam, Primidone and Venlafaxine present higher levels of 
concentration in the water of the exit than in the water of the entrance, so they present negative 
efficiencies. As it has been mentioned before, the fact of founding pharmaceuticals with higher 
concentrations in the treated water has been already analysed in the scientific research. 
Moreover, the uncertainty associated to the calculations need to be considered because the 
water from the effluent of the following day was compared with the water from the influent of 
the previous day, so 24h is the estimated time of residence in the WWTP. 
 
 



























Table 11. Removal efficiency (%) of pharmaceuticals, where the weekday specified refers to the day of 
collection of EWW. 
Drugs Tuesday Wednesday Thursday Friday Saturday Sunday Average 
Acetaminophen 100 100 100 100 100 100 100 
Alprazolam a a a a e c a 
Atorvastatin c 100 100 c 100 100 100 
Azithromycin b b b b b b b 
Bezafibrate - - - - - - - 
Carbamazepine b b b 0 0 b b 
Ciprofloxacin n.c. n.c. n.c. n.c. n.c. n.c. n.c. 
Clarithromycin 71.4 48.5 73.9 29.9 51.6 61.9 56.2 
Clindamycin A - a a a d a 
Diclofenac 71.8 50.4 27.8 41 41.5 57.6 48.4 
Enalapril 100 100 - - 100 100 100 
Erythromycin e 35.6 -30.8 34.5 d 40.6 20 
Furaltadone - - - - - - - 
Gabapentin 65 64.1 65.1 64.8 73.2 71.1 67 
Gemfibrozil - - - - - - - 
Irbesartan 52.5 39.6 0.3 28.9 38.6 33.7 32.3 
Ketoprofen - - - - - - - 
Levamisol 13.8 e 36.5 21.2 36.7 25.4 26.7 
Lincomycin - - - - - - - 
Lorazepam 1.3 -23.3 25.7 -50.8 e e -11.7 
Losartan 93.6 95.2 c 94.4 93.4 c 94.1 
Metoprolol 0 0 b e d 0 0 
Metronidazole 0 b 0 - a b 0 
Nalidixic acid 0 a a - - a a 
Naproxen - b b b - b b 
Norfloxacin n.c. n.c. n.c. n.c. n.c. n.c. n.c. 
Omeprazole 
sulfide, 4-OH 
52.8 47.4 44.6 39.8 61.2 60.4 51.3 
Oxolinic acid e - - - - - - 
Pantoprazole e e e e e e e 
Phenazone c - 0 0 a 0 0 
Primidone 44.1 15.5 -3.4 15.2 16.4 8.2 16 
Roxithromycin - - b - - - - 
Salbutamol 
(Albuterol) 
a 0 0 0 0 0 0 
Simvastatin - - - - - - - 
Sulfadiazine - - - - - - - 
Sulfamethoxazole 50.3 75.8 56.7 68 77.2 66.2 65.7 
Tetracycline 53.7 70 - - - a 61.9 
Tramadol 30.5 23.3 20.7 100 1.6 66.7 40.5 
Trimethoprim 93.7 95.7 100 79.6 100 c 93.8 
Valsartan 94.9 100 100 94.6 97 97.6 97.4 
Venlafaxine 6.2 7 -10.2 6.6 36.5 10.1 9.4 
-. Not detected. a. When an undetected compound appears after treatment but cannot be quantified. b. When a 
compound detected but not quantified is no longer detected in the EWW sample. c. When a compound is detected 
after treatment, but quantification is not possible. d. When a compound is detected before treatment and can be 
quantified afterwards.  e. When compound is not detected is quantified after passing through the WWTP. n.c. Not 
calculated as being indicative data. 0. When compound is detected in both influent and effluent samples. 




4.4. Comparison of pharmaceuticals prevalence in IWW and 
Hospital water 
 
When comparing Table 6 and Table 10, it can be observed that most of pharmaceuticals 
from the Hospital samples presented average concentrations significantly higher than in urban 
IWW.  
 
With the purpose of visually illustrate the differences between the streams that enter 
in the WWTP, Figure 5 compares the average weekly concentration of pharmaceuticals in both 
Hospital water and IWW. Only Clarithromycin, Irbesartan, Levamisol, Primidone and Tetracycline 
showed a slightly higher average concentration in the water of the entrance into the WWTP 
than the Hospital sewage. Levamisol and Primidone were not detected in the water of the 
Hospital, but they presented an average concentration in the IWW waters of 29 ng/L and 76 
ng/L respectively. 
 
 Acetaminophen and Gabapentin presented the highest average concentration in both 
the Hospital WW and the IWW samples. Acetaminophen (i.e. the active principle of 
Paracetamol) is a daily used pharmaceutical that is first in the ranking of the consumption of 
analgesics’ active principles (Sanitarios, 2019). Moreover, it is second in the ranking of the first 
twenty active principles with the highest consumption in containers (Ministerio de Sanidad, 
2019). Therefore, it is understandable that it presents high concentrations in wastewater. On 
the other hand, the high levels of Gabapentin seems surprising because it is not in the ranking 
of the twenty active principles with the highest consumption in containers (Ministerio de 
Sanidad, 2019). However, it must be taken into account the metabolism of the pharmaceutical, 
because it highly influences the levels of the parent compound excreted. Thus, it may occur that 
a compound reaches high levels in WW not only due to its high consumption but also to its low 
metabolism in humans, i.e. cases when the parent compound is the main product excreted in 
urine. This seems to be the situation for Gabapentin. Other studies (Goodman, C. W., & Brett, 
2017; Mondón, S., Nogué, S., Urbano, D., & Rovira, 2010) have shown an increasing 
Gabapentin’s prescription and consumption, although there are concerns about its possible 
misuse and abuse.  
 
4.5. Environmental risk assessment 
 
The continued introduction of PPCPs into the aquatic environment as well as their 
bioactivity and known modes of action, convert them to emerging contaminants, which may 
have ecotoxicological effects on aquatic and terrestrial organisms and public health (X. Liu et al., 
2020), and may produce antibiotic resistance and endocrine disruptions on humans (M. Liu et 
al., 2019). Therefore, the assessment of their potential effect in the environmental 
compartment is of utmost importance for a sustainable aquatic system. 
 
For this purpose, the parameter known as HQ has been estimated in order to evaluate 
the impact of the pharmaceuticals in the aquatic environment. The HQ has been calculated for 
treated water dividing the concentration of each identified pharmaceutical in the EWW with by 
its PNEC (Predicted No Effect Concentration) value, as shown in Equation 4.  
 













CEWW corresponds to the weekly average concentration of the pharmaceutical (ng/L) in 
the effluent sample (shown in Table 8). Furthermore, the PNEC value has been taken from the 
literature, and is shown in Table 12 together with the calculated value of the HQ. 
 
Among the 22 HQ calculated values, only 4 showed a HQ higher than 1, the value taken 
as a reference in risk assessment: Ciprofloxacin (40.85), Diclofenac (2.86), Norfloxacin (1.33) and 
Venlafaxine (4.53). As previously mentioned, the concentrations of the pharmaceuticals 
Ciprofloxacin and Norfloxacin must be taken as an estimated value, so the HQ values are also 
approximate values, but they are sufficiently high values to be taken into account, particularly 
for Ciprofloxacin. Moreover, Diclofenac and Venlafaxine are considered to have higher impact 
in the aquatic environment as the HQ is above 1.  
 
In general, the obtained results are satisfactory from an environmental point of view 
because almost all the pharmaceuticals presented HQ lower than 1. However, it must be 
considered that these estimations have been made considering the parent pharmaceuticals 
only, regardless their metabolites. Previous research (Han & Lee, 2017) has reported that 
pharmaceuticals’ metabolites may produce similar, even higher risk in the aquatic environment 
than the pharmaceuticals themselves. For this reason, it would be interesting in future works to 
include, at least some relevant metabolites, in both studies on occurrence in wastewater and 
environmental risk assessment. 
 


































Table 12. PNEC data and calculated HQ values. 
Compound CAS No. 
PNEC           
(µg/L) 
HQ Reference 
Acetaminophen 103-90-2 134 - (Network, 2020) 
Alprazolam  28981-97-7 0.077 0.08 (Network, 2020) 
Atorvastatin 134523-00-5 0.01 - (Network, 2020) 
Azithromycin 83905-01-5 0.019 - (Network, 2020) 
Bezafibrate 41859-67-0 2.3 - (Network, 2020) 
Carbamazepine 298-46-4 0.05 - (Network, 2020) 
Ciprofloxacin 85721-33-1 0.089 40.85 (Network, 2020) 
Clarithromycin 81103-11-9 0.12 0.40 (Network, 2020) 
Clindamycin 18323-44-9 1.7 - (Network, 2020) 
Diclofenac 15307-86-5 0.05 2.86 (Network, 2020) 
Enalapril 75847-73-3 1.58 - (Network, 2020) 
Erythromycin 114-07-8 0.2 0.14 (Network, 2020) 
Furaltadone 139-91-3 19.2 - (Network, 2020) 
Gabapentin 60142-96-3 10 0.16 (Network, 2020) 
Gemfibrozil 25812-30-0 0.5 - (Network, 2020) 
Irbesartan 138402-11-6 704 0 (Network, 2020) 
Ketoprofen 22071-15-4 2.1 - (Network, 2020) 
Levamisole 14769-73-4 1.81 0.02 (Network, 2020) 
Lincomycin  154-21-2 3.95 - (Network, 2020) 
Lorazepam 846-49-1 0.096 0.46 (Network, 2020) 
Losartan 114798-26-4 78 0 (Network, 2020) 
Metoprolol 37350-58-6 8.6 0 (Network, 2020) 
Metronidazole 
443-48-1 6.76 - 
(Wielens Becker 
et al., 2020) 
Nalidixic acid 389-08-2 8.98 - (Network, 2020) 
Naproxen 
22204-53-1 1570 - 
(Wielens Becker 
et al., 2020) 
Norfloxacin 70458-96-7 0.78 1.33 (Network, 2020) 
Omeprazole sulfide, 4-OH 103876-98-8 0.26 0.15 (Network, 2020) 
Oxolinic acid 14698-29-4 1.07 0.02 (Network, 2020) 
Pantoprazole 102625-70-7 0.68 0.03 (Network, 2020) 
Phenazone 60-80-0 21.1 - (Network, 2020) 
Primidone 125-33-7 9.11 0.01 (Network, 2020) 
Roxithromycin 80214-83-1 0.083 - (Network, 2020) 
Salbutamol (Albuterol) 18559-94-9 17.1 - (Network, 2020) 
Simvastatin 79902-63-9 2.63 - (Network, 2020) 
Sulfadiazine 68-35-9 1 - (Network, 2020) 
Sulfamethoxazole 723-46-6 0.6 0.06 (Network, 2020) 
Tetracycline 60-54-8 0.5 0.05 (Network, 2020) 
Tramadol 27203-92-5 8.65 0.06 (Network, 2020) 
Trimethoprim 738-70-5 120 0 (Network, 2020) 
Valsartan 137862-53-4 560 0 (Network, 2020) 
Venlafaxine  93413-69-5 0.038 4.53 (Network, 2020) 











5. Conclusions  
 
A total of 41 pharmaceuticals have been determined (identification and quantification) 
by UHPLC-MS/MS with QqQ in raw influent and effluent wastewater from a WWTP in the north 
Spain. In this way, the occurrence of these compounds in both types of water have been 
evaluated, as well as the removal efficiency at the wastewater treatment plant for the selected 
pharmaceuticals. In addition, on the basis of concentrations found in treated water (effluent) 
the potential hazardous effect of these contaminants in the environment has been assessed. In 
order to support the reliability of quantitative data reported, several QCs were prepared and 
analysed in every batch of samples, showing recovery values between 60% and 140% for the 
great majority of compounds under study. 
 
Most of the compounds were found in the IWW entering into the WWTP and in the 
Hospital discharge, illustrating the consumption of the pharmaceuticals in the population. The 
high concentration of Acetaminophen and Gabapentin stood out in comparison to the other 
pharmaceuticals. The removal efficiency of the plant was studied by comparing the mass loads 
in IWW and EWW samples. In general, the wastewater treatment plant was able to remove, at 
least partially, a major part of the pharmaceuticals. However, only Acetaminophen, Atorvastatin 
and Enalapril were totally eliminated. Hazard quotients were calculated from the concentration 
data obtained from the EWW samples to assess the potential hazard posed by their presence in 
the aquatic system. HQ was calculated for each pharmaceutical as the ratio between the 
concentration found in EWW and the PNEC value, which was based on data reported by the 
scientific literature. PNEC refers to the concentration that will probably not have any toxic effect. 
Only 4 compounds presented HQ > 1, the value taken as reference to consider a risk in the 
aquatic environment. Ciprofloxacin, with a HQ of 40.85 is remarkable because suggesting high 
aquatic environmental risk. Furthermore, Diclofenac, Norfloxacin and Venlafaxine also shown a 
hazard quotient higher than 1.  
 
This work shows that although most of pharmaceuticals are partially removed in the 
WWTP, the treatments applied should be improved for a more efficient elimination. At present, 
with the conventional treatments applied in the WWTP, most of the pharmaceuticals released 
into the environmental do not pose a significant risk to the aquatic environment, but still four 
compounds are found at levels that may suppose an hazard that would notably decrease by 
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Monday Thuesday Wednesday Thursday Friday Saturday Sunday
IWW
Acetaminophen Atorvastatin Ciprofloxacin Clarithromycin Diclofenac
Enalapril Erythromycin Gabapentin Irbesartan Levamisol
Lorazepam Losartan Norfloxacin Omeprazole sulfide, 4-OH Primidone

















Monday Thuesday Wednesday Thursday Friday Saturday Sunday
IWW
Acetaminophen Atorvastatin Clarithromycin Diclofenac Enalapril
Erythromycin Gabapentin Irbesartan Levamisol Lorazepam
Losartan Norfloxacin Omeprazole sulfide, 4-OH Primidone Sulfamethoxazole














Monday Thuesday Wednesday Thursday Friday Saturday Sunday
EWW
Ciprofloxacin Clarithromycin Diclofenac Erythromycin Gabapentin
Irbesartan Levamisol Lorazepam Losartan Norfloxacin
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Clarithromycin Diclofenac Erythromycin Gabapentin Irbesartan
Levamisol Lorazepam Losartan Norfloxacin Omeprazole sulfide 4-OH
















Monday Thuesday Wednesday Thursday Friday Saturday Sunday
Hospital
Acetaminophen Atorvastatin Azithromycin Ciprofloxacin Clindamycin
Diclofenac Enalapril Erythromycin Gabapentin Irbesartan
Lorazepam Losartan Norfloxacin Omeprazole sulfide, 4-OH Pantoprazole
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Atorvastatin Azithromycin Clindamycin Diclofenac Enalapril
Erythromycin Gabapentin Irbesartan Lorazepam Losartan
Norfloxacin Omeprazole sulfide, 4-OH Pantoprazole Phenazane Salbutamol
Tramadol Trimethoprim Valsartan Venlafaxine
 
 
 
 
